65 related articles for article (PubMed ID: 30284405)
21. Cervical cancer screening cotesting with cytology and MRNA HPV E6/E7 yields high rates of CIN2+ lesions in young women.
Granados R; Tellez-Safina H; Solis I; Mateos F; Rodriguez-Barbero JM; Aramburu JA; Huertas MA; Bajo P; Camarmo E; Corrales T; Medina P; Calvo B; Martin E; Anta L; Zamora M; Alcaide T
Diagn Cytopathol; 2017 Dec; 45(12):1065-1072. PubMed ID: 28949442
[TBL] [Abstract][Full Text] [Related]
22. Determinants of Viral Oncogene E6-E7 mRNA Overexpression in a Population-Based Large Sample of Women Infected by High-Risk Human Papillomavirus Types.
Giorgi Rossi P; Bisanzi S; Allia E; Mongia A; Carozzi F; Gillio-Tos A; De Marco L; Ronco G; Gustinucci D; Del Mistro A; Frayle H; Iossa A; Fantacci G; Pompeo G; Cesarini E; Bulletti S; Passamonti B; Rizzi M; Penon MG; Barca A; Benevolo M
J Clin Microbiol; 2017 Apr; 55(4):1056-1065. PubMed ID: 28100595
[TBL] [Abstract][Full Text] [Related]
23. HPV testing by cobas HPV test in a population from Catalonia.
Lloveras B; Gomez S; Alameda F; Bellosillo B; Mojal S; Muset M; Parra M; Palomares JC; Serrano S
PLoS One; 2013; 8(3):e58153. PubMed ID: 23483984
[TBL] [Abstract][Full Text] [Related]
24. Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis.
Figueiredo D; Ribeiro I; Penedones A; Mendes D; Alves C; Batel-Marques F; da Silva DP
BMC Womens Health; 2023 Mar; 23(1):96. PubMed ID: 36894908
[TBL] [Abstract][Full Text] [Related]
25. Clinical performance of the Roche Cobas 4800 HPV test for primary cervical cancer screening in a Chinese population.
Liu SS; Chan KKL; Wei TN; Tse KY; Ngu SF; Chu MMY; Lau LSK; Cheung ANY; Ngan HYS
PLoS One; 2022; 17(8):e0272721. PubMed ID: 35930575
[TBL] [Abstract][Full Text] [Related]
26. HPV testing for cervical cancer screening: technical improvement of laboratory logistics and good clinical performance of the cobas 6800 in comparison to the 4800 system.
Frayle H; Gori S; Rizzi M; Graziani BN; Vian E; Giorgi Rossi P; Del Mistro A
BMC Womens Health; 2019 Mar; 19(1):47. PubMed ID: 30909894
[TBL] [Abstract][Full Text] [Related]
27. Clinical Performance of SurePath™ Preservative Compared to PreservCyt® with Cobas® and Hybrid Capture® 2 HPV Tests in a Colposcopy Population.
Pyne MT; Tardif KD; Allen A; Sexsmith C; Lesher L; Adelman M; Janát-Amsbury MM; Schlaberg R
Clin Lab; 2019 Mar; 65(3):. PubMed ID: 30868858
[TBL] [Abstract][Full Text] [Related]
28. Effect of preanalytical processing of ThinPrep specimens on detection of high-risk human papillomavirus by the Aptima HPV assay.
Munson E; Schroeder ER; Ross KC; Yauck C; Bieganski T; Amrhein RD; Napierala M; Harkins AL
J Clin Microbiol; 2014 May; 52(5):1448-52. PubMed ID: 24554753
[TBL] [Abstract][Full Text] [Related]
29. Comparing the performance of six human papillomavirus tests in a screening population.
Cuzick J; Cadman L; Mesher D; Austin J; Ashdown-Barr L; Ho L; Terry G; Liddle S; Wright C; Lyons D; Szarewski A
Br J Cancer; 2013 Mar; 108(4):908-13. PubMed ID: 23370211
[TBL] [Abstract][Full Text] [Related]
30. SurePath Specimens Versus ThinPrep Specimen Types on the COBAS 4800 Platform: High-Risk HPV Status and Cytology Correlation in an Ethnically Diverse Bronx Population.
Naeem RC; Goldstein DY; Einstein MH; Ramos Rivera G; Schlesinger K; Khader SN; Suhrland M; Fox AS
Lab Med; 2017 Aug; 48(3):207-213. PubMed ID: 28379422
[TBL] [Abstract][Full Text] [Related]
31. 5-type HPV mRNA versus 14-type HPV DNA test: test performance, over-diagnosis and overtreatment in triage of women with minor cervical lesions.
Westre B; Giske A; Guttormsen H; Sørbye SW; Skjeldestad FE
BMC Clin Pathol; 2016; 16():9. PubMed ID: 27279798
[TBL] [Abstract][Full Text] [Related]
32. An evaluation of solid versus liquid transport media for high-risk HPV detection and cervical cancer screening on self-collected specimens.
Du H; Duan X; Liu Y; Shi B; Zhang W; Wang C; Qu X; Bao J; Li J; Zhao C; Jiang J; Liu J; Wu K; Xiao A; Duan L; Huang X; Bian S; Zhang L; Luo H; Wei L; Belinson JL; Wu R;
Infect Agent Cancer; 2020 Nov; 15(1):72. PubMed ID: 33292341
[TBL] [Abstract][Full Text] [Related]
33. Disagreement between human papillomavirus assays: an unexpected challenge for the choice of an assay in primary cervical screening.
Rebolj M; Preisler S; Ejegod DM; Rygaard C; Lynge E; Bonde J
PLoS One; 2014; 9(1):e86835. PubMed ID: 24466262
[TBL] [Abstract][Full Text] [Related]
34. HPV Tests Comparison in the Detection and Follow-Up after Surgical Treatment of CIN2+ Lesions.
Bottari F; Iacobone AD; Radice D; Preti EP; Preti M; Franchi D; Boveri S; Sandri MT; Passerini R
Diagnostics (Basel); 2022 Sep; 12(10):. PubMed ID: 36292048
[TBL] [Abstract][Full Text] [Related]
35. Comparative pilot study about HPV test with partial genotyping in primary screening versus other strategies for cervical cancer population screening, CRYGEN 16/18 study.
Hernández-Aguado JJ; de La Fuente-Valero J; Ramírez Mena M; Ortega-Medina L; Vidart Aragón JA; Galán JC
Enferm Infecc Microbiol Clin (Engl Ed); 2021 Aug; ():. PubMed ID: 34404547
[TBL] [Abstract][Full Text] [Related]
36. Raman Spectroscopy of Liquid-Based Cervical Smear Samples as a Triage to Stratify Women Who Are HPV-Positive on Screening.
Traynor D; Martin CM; White C; Reynolds S; D'Arcy T; O'Leary JJ; Lyng FM
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33921939
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of an isothermal amplification HPV detection assay for primary cervical cancer screening.
Zhang W; Du H; Huang X; Wang C; Duan X; Liu Y; Shi B; Zhang W; Qu X; Wei L; Schiffman M; Belinson JL; Wu R
Infect Agent Cancer; 2020; 15():65. PubMed ID: 33110442
[TBL] [Abstract][Full Text] [Related]
38. Corrigendum to CINtec PLUS and cobas HPV testing for triaging Canadian women referred to colposcopy with a history of low-grade squamous intraepithelial lesion: Baseline findings [Papillomavirus Res. 10 (2020) 100206].
Ratnam S; Jang D; Gilbert L; Alaghehbandan R; Schell M; Needle R; Ecobichon-Morris A; Wang PP; Rahman M; Costescu D; Elit L; Zahariadis G; Chernesky M
Tumour Virus Res; 2021 Jun; 11():200215. PubMed ID: 33741546
[No Abstract] [Full Text] [Related]
39. Correction: Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis.
Figueiredo D; Ribeiro I; Penedones A; Mendes D; Alves C; Batel-Marques F; da Silva DP
BMC Womens Health; 2024 Feb; 24(1):102. PubMed ID: 38331784
[No Abstract] [Full Text] [Related]
40. The coming human papillomavirus (HPV) test-driven colposcopy tsunami.
Austin RM
J Am Soc Cytopathol; 2017; 6(5):177-179. PubMed ID: 31043239
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
